On October 22, 2020, Precision Nanosystems, Inc. ("PNI") announced that it had received a commitment of up to $18.2 million from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

Paul Armitage of Gowling WLG advised PNI with respect to the negotiation of this contribution agreement with the Government of Canada.